###begin article-title 0
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Refined study of the interaction between HIV-1 p6 late domain and ALIX
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 248 249 248 249 <bold xmlns:xlink="http://www.w3.org/1999/xlink">L</bold>
###xml 252 254 252 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 255 256 255 256 <bold xmlns:xlink="http://www.w3.org/1999/xlink">L</bold>
###xml 258 259 258 259 <bold xmlns:xlink="http://www.w3.org/1999/xlink">L</bold>
###xml 261 262 261 262 <bold xmlns:xlink="http://www.w3.org/1999/xlink">L</bold>
###xml 264 265 264 265 <bold xmlns:xlink="http://www.w3.org/1999/xlink">L</bold>
###xml 625 633 625 633 <sub xmlns:xlink="http://www.w3.org/1999/xlink">391&#8211;510 </sub>
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 136 141 <span type="species:ncbi:4932">yeast</span>
###xml 770 774 <span type="species:ncbi:11665?1.0">EIAV</span>
The interaction between the HIV-1 p6 late budding domain and ALIX, a class E vacuolar protein sorting factor, was explored by using the yeast two-hybrid approach. We refined the ALIX binding site of p6 as being the leucine triplet repeat sequence (Lxx)4 (LYPLTSLRSLFG). Intriguingly, the deletion of the C-terminal proline-rich region of ALIX prevented detectable binding to p6. In contrast, a four-amino acid deletion in the central hinge region of p6 increased its association with ALIX as shown by its ability to bind to ALIX lacking the proline rich domain. Finally, by using a random screening approach, the minimal ALIX391-510 fragment was found to specifically interact with this p6 deletion mutant. A parallel analysis of ALIX binding to the late domain p9 from EIAV revealed that p6 and p9, which exhibit distinct ALIX binding motives, likely bind differently to ALIX. Altogether, our data support a model where the C-terminal proline-rich domain of ALIX allows the access of its binding site to p6 by alleviating a conformational constraint resulting from the presence of the central p6 hinge.
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 322 323 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 328 329 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">s</italic>
###xml 339 340 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 350 351 350 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 352 353 352 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 371 374 371 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ALG</italic>
###xml 377 378 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i</italic>
###xml 401 402 401 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 403 404 403 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 171 176 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A variety of enveloped viruses use for budding the host machinery that is required for the inward vesiculation of the membrane of the multivesicular bodies (MVB) [1]. For HIV-1 virus, this process is in part mediated through physical interactions between the viral Gag-p6 late domain and the host cellular factors Tsg101 (tumor suppressor gene 101) [2-6], and AIP1/ALIX (ALG-2 interacting protein X) [4,6].
###end p 4
###begin p 5
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 222 227 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 240 244 <span type="species:ncbi:11665?1.0">EIAV</span>
In this context, the reduction of Tsg101 levels by siRNA or the introduction of a dominant-negative Tsg101 mutant severely blocks viral budding [7,8], while the disruption of the p6-ALIX interaction is less detrimental to HIV-1 budding. In EIAV, another member of the lentivirus subfamily of retrovirus, the Gag-p9 late domain contains a unique ALIX-binding motif (YPDL), which supports the release of virions in the absence of the Tsg101 cofactor.
###end p 5
###begin p 6
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Mechanistically, the interaction between p6 and Tsg101 is well-characterized: Tsg101 interacts with the p6 PTAP motif via its N-terminal UEV domain in a process that appears to be up-regulated when p6 becomes monoubiquitinylated at conserved Lys residues in positions 27 and 33 [3,7,9,10]. The structure of the Tsg101 UEV domain in complex with a 9-amino acid p6 peptide containing a central PTAP motif has been solved in solution by RMN [11,12].
###end p 6
###begin p 7
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 255 263 255 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 373 374 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 620 622 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 623 625 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 851 853 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 698 703 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The other p6-interacting partner, ALIX, which consists of 868 amino acids, is organized in three domains: (i) a N-terminal BroI domain responsible for CHMP4 recruitment in the endosomal pathway [13,14], (ii) a middle region (aa. 362-702), which interacts in vivo with p6 and p9 late domains [15], and (iii) a long C-terminal proline-rich region (PRR) that binds to Tsg101 [6]. Based on recent crystallographic data, the ALIX central region has been shown to adopt a "V" shape, which is the result of the complex arrangement of 11 alpha-helices with connecting loops that cross three times between the two arms of the V [16,17]. When overexpressed in mammalian cells, the V domain strongly inhibits HIV-1 particles release, and this inhibition is reversed by mutations of amino acid residues that specifically block binding of the ALIX V domain to p6 [18].
###end p 7
###begin p 8
###xml 12 21 12 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 877 879 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 99 103 <span type="species:ncbi:11665?1.0">EIAV</span>
###xml 154 159 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 398 402 <span type="species:ncbi:11665?1.0">EIAV</span>
By using an in vitro pull-down approach, Strack et al., (2003) [4] have noted that the affinity of EIAV p9 for ALIX was significantly higher than that of HIV-1 p6. This suggests that the presence of a more efficient ALIX-binding site in p9 may compensate for the absence of a Tsg101 binding site. Such differences could be due in part to some intrinsic properties of the p6 polypeptide: (i) the p9 EIAV prototype motif L/IYPxL of different Gag late domains recognized by ALIX is only partially conserved in Gag-p6, where an adjacent LxxLF motif seems important for binding and, (ii) p6 adopts a random conformation in water without any preference for secondary structure [19]. However, under more hydrophobic conditions, i.e. in the presence of 50% aqueous TFE, p6 exhibits a functional helix-flexible-helix conformation, as assessed by its ability to bind to the Vpr protein [20].
###end p 8
###begin p 9
###xml 345 350 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 368 372 <span type="species:ncbi:11665?1.0">EIAV</span>
###xml 455 460 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The following work revealed that specific p6-ALIX association could be achieved through contacts between a minimal ALIX fragment containing amino acids residues 391-510 in the long arm of the V domain and a p6 late domain which has been mutated in its central hinge region. This mutant which displayed intermediary affinity for ALIX compared to HIV-1 p6 wild type and EIAV p9, suggests that in physiological conditions the constrained conformation of the HIV-1 late domain weakens its association with ALIX.
###end p 9
###begin title 10
Findings
###end title 10
###begin title 11
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
###xml 33 38 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Yeast two-hybrid analysis of the HIV-1 p6-ALIX interaction
###end title 11
###begin p 12
###xml 31 39 31 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 59 63 <span type="species:ncbi:11665?1.0">EIAV</span>
###xml 181 186 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 284 289 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 574 579 <span type="species:ncbi:4932">yeast</span>
###xml 814 819 <span type="species:ncbi:4932">yeast</span>
Several studies concerning the in vivo interaction between EIAV p9 and ALIX were previously designed using the Y2H assay [15,21]. For comparison, we examined for the first time the HIV-1 p6-ALIX interaction using a similar approach. Close characterization of the ALIX-binding site in HIV-1 p6 was accomplished by systematically introducing alanine mutations at every amino acid residue contained within the p6 minimal region (aa: 31-46) that had been previously implicated in ALIX recognition [4]. These Gal4 DBD-p6 bait constructs were individually co-transformed into the yeast strain AH 109 with a prey plasmid encoding the ALIX protein (868 amino acid-long) fused to the Gal4 AD. Relative quantification of the protein/protein interaction strength was monitored by measuring the beta-galactosidase activity in yeast cells cotransformed with bait and prey expressing plasmids.
###end p 12
###begin p 13
###xml 19 21 19 21 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 97 99 97 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 172 174 172 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 366 374 366 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 848 857 848 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 883 885 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 982 991 982 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1022 1024 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1025 1027 1025 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 190 195 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
As shown in Figure 1A, the alanine scan clearly revealed that both amino acid residues in the YPxn L consensus sequence as well as the leucine triplet repeat sequence (Lxx)4 are crucial for HIV-1 p6 to interact with ALIX. This motif overlaps completely with the helix-2 in p6 as identified by NMR analysis [20], thus indicating that the ability of complex formation in vivo closely depends on the complete integrity of the secondary structure of helix-2. In details, the alanine substitution has variable effect from complete abolition of binding for Y36A and L38A, severe reduction in binding for E34A, L35A, P37A, L41A, R42A and a moderate but significant reduction for L44A, while the substitution of all other residues were well tolerated. Collectively, the binding data of our p6 mutants, are in full agreement with experimental data obtained in vitro with p6-derived peptides [18], except for the poor binding activity of L35A mutant, that has not been previously found in an in vitro binding assay measured by SPR [16-18]. However, the same authors reported that the corresponding L22A mutation in p9, completely abrogates p9 binding to ALIX. Thus, both L35 in p6 and L22 in p9 late domains are critical residues in the binding to ALIX.
###end p 13
###begin p 14
###xml 0 70 0 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Yeast two hybrid interaction between the HIV-1 p6 late domain and ALIX</bold>
###xml 1308 1311 1285 1288 <sub xmlns:xlink="http://www.w3.org/1999/xlink">UK </sub>
###xml 1317 1323 1294 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bro1: </italic>
###xml 1351 1354 1328 1331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRR</italic>
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 143 148 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 429 434 <span type="species:ncbi:4932">Yeast</span>
###xml 748 753 <span type="species:ncbi:4932">yeast</span>
###xml 905 910 <span type="species:ncbi:4932">Yeast</span>
###xml 1021 1026 <span type="species:ncbi:4932">yeast</span>
###xml 1276 1281 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Yeast two hybrid interaction between the HIV-1 p6 late domain and ALIX. (A) Alanine-scanning mutagenesis of the ALIX-binding region of p6. The HIV-1 p6 (pNL4-3, NIH AIDS Research and Reference Reagent Program) derived-DNA fragment was generated by PCR and inserted in frame with the Gal4-DBD of pGBKT7 (Clonetech). ALIX was PCR-generated from plasmid pGAD AIP-1/ALIX [23] and fused in frame with the Gal4 AD of pACT2 (Clontech). Yeast strain AH109 (MATa, trp-901, leu2-3, 112, ura3-52, his3-200, gal4Delta, gal80Delta, LYS2::GAL1UAS-GAL1TATA-HIS3, GAL2UAS-GAL2TATA-ADE2; URA3::MEL1UAS-MEL1TATA-lacZ, MEL1) was cotransformed with pGBKT7 and pACT2 derivatives. The relative strength of the protein interaction between bait and prey was determined in yeast transformants grown at 30degreesC in SD/-Leu/-Trp selection medium by measuring beta-galactosidase activity according to the protocol described in the Yeast beta-Galactosidase Assay Kit from Pierce. Values are referred to 100% beta-galactosidase activity measured in yeast cells cotransformed with wild-type p6 and ALIX proteins. Liquid culture assays were performed in triplicate. In the histogram, the lack of activity is indicated by triangles. (B). ALIX and fragments thereof were tested for interaction with Gal4 DBD-HIV-1 p6 and/or GAL4 DBD-p9 EIAVUK [33]. Bro1: Bro1-rhophilin-like domain; PRR: proline-rich region. Deletions and point mutations were generated using a splice-overlap extension method [34]. A reference value of 1 was set to beta-galactosidase activity resulting from the interaction of ALIX with either p9 or p6 wild-type proteins. The lack of activity is indicated by triangles.
###end p 14
###begin p 15
###xml 287 295 287 291 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;PRR</sub>
###xml 353 360 349 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 408 410 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 421 430 417 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 571 573 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 204 208 <span type="species:ncbi:11665?1.0">EIAV</span>
In subsequent experiments, we tested in the Y2H system the potential interaction between the p6 domain and different ALIX mutant constructs. Side-by-side comparison was carried out in the presence of the EIAV p9 domain. Unexpectedly, a truncation of the proline-rich region in ALIX (ALIXDeltaPRR) from amino acids 716 to 868 impaired ALIX binding to p6 in vivo, while p9 still bound to the ALIX mutant (Fig. 1B). Because in vitro ALIX deleted from PRR has a lower affinity for p6 than for p9 (dissociation constants measured by SPR are 60 muM and 1.2 muM, respectively) [16], our data point out to a major role of PRR as positive regulator for the ALIX-p6 interaction.
###end p 15
###begin p 16
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 427 440 427 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;541&#8211;582 </sub>
###xml 446 448 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 577 584 573 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
The region 541 to 582 contains essentially helix-7 residues in the arm 1 of the V domain (nomenclature is from [17]) and could play a key role in ALIX oligomerization. Indeed, bioinformatic analyses using the MultiCoil prediction program [22] suggested that this region in ALIX has a high probability for forming a trimeric coiled-coil (with a maximum trimeric residue probability value of 0.691 for S575). Y2H analysis of ALIXDelta541-582 (Fig. 1B) provides evidence that helix 7 (and probably oligomerization of ALIX protein) is dispensable for interaction with p6 and/or p9 in vivo.
###end p 16
###begin p 17
###xml 395 404 387 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 405 407 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
From structural studies, the ALIX viral late domain-binding site has been mapped to a large hydrophobic pocket on the long arm of the V domain. Mutational experiments targeting amino acid residues, which form the surrounding walls, revealed in particular that substitutions V509A in alpha5 and F676D in alpha11 caused a dramatic effect on the ability of the protein to bind a p6-derived peptide in vitro [17].
###end p 17
###begin p 18
###xml 78 86 78 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 764 766 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1105 1107 1093 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1323 1325 1311 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 169 174 <span type="species:ncbi:4932">yeast</span>
###xml 559 564 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1192 1204 <span type="species:ncbi:11191">Sendai virus</span>
The effect of these two mutations on interaction with p6 and p9 was evaluated in vivo using the Y2H assay. As expected, both the V509A and F676D mutations prevented the yeast cell growth on selective medium when tested against the bait-p6 protein (Fig. 1B). Quite different results were obtained with p9, since the V509A mutation was well tolerated. Taken together, these results are consistent with a model in which the intact conformation of the binding site is required for the efficient interaction between ALIX and the helix-2 amino acid residues in the HIV-1 p6 late domain. In this regard, it has been postulated that p6 may bind coaxially to the V domain hydrophobic pocket and form a four-helix bundle together with ALIX alpha- 4, alpha- 5 and alpha- 11 [17]. The molecular mechanisms by which p9 binds to ALIX are likely involving a less stringent process in terms of structural requirement and integrity of the late domain binding site. Indeed, the short YPDL tetrapeptide motif detected in p9 constitutes a specific binding epitope for AIP1 family members throughout the eukaryotic evolution [23]. Moreover, this motif appears very stringent since the close YLDL motif within the Sendai virus M protein, binds to the Bro1 domain of ALIX between amino acid residues 1-211, i.e. outside of the p9 binding domain [24].
###end p 18
###begin title 19
###xml 17 22 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Description of a HIV-1 p6 mutant with increased ALIX-binding affinity
###end title 19
###begin p 20
###xml 200 209 200 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 238 239 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 239 241 239 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d </italic>
###xml 239 241 239 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>d </italic></sub>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 114 118 <span type="species:ncbi:11665?1.0">EIAV</span>
Isothermal titration calorimetry experiments performed on the HIV-1 p6-derived peptide (DKELYPLTSLRSLFGN) and the EIAV p9-derived peptide (QTQNLYPDLSEIKKE) have reported that both peptides interacted in vitro with ALIX with quite similar Kd values [18], while full-length p6 displayed a much lower ALIX-binding affinity when compared to p9 [16]. A possible explanation for such divergent behaviour is that p6 could exhibit a constrained conformation for ALIX binding. Analysis of the high resolution structure of p6 [20] (Fig. 2A) suggests that the hinge region (aa: 19-32) in the vicinity of the ALIX-binding site (helix alpha- 2) may play such a structural function.
###end p 20
###begin p 21
###xml 32 41 32 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ</sub>
###xml 0 58 0 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Characterization of the HIV-1 p6<sub>&#916;SQKQ</sub>-ALIX interaction</bold>
###xml 133 143 129 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
###xml 204 213 196 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;PRR </sub>
###xml 435 444 419 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQK </sub>
###xml 571 581 551 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
###xml 742 750 718 722 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;PRR</sub>
###xml 1152 1158 1124 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Input </italic>
###xml 1572 1582 1536 1542 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
###xml 2011 2015 1971 1975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 64 69 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 113 118 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 147 151 <span type="species:ncbi:11665?1.0">EIAV</span>
###xml 230 235 <span type="species:ncbi:4932">yeast</span>
###xml 559 564 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 585 589 <span type="species:ncbi:11665?1.0">EIAV</span>
###xml 1348 1351 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1450 1453 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1787 1792 <span type="species:ncbi:10090">mouse</span>
###xml 1807 1810 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2037 2042 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Characterization of the HIV-1 p6DeltaSQKQ-ALIX interaction. (A) HIV-1 p6 (1-52) structure according to [20]. (B) HIV-1 p6 (1-52), p6 DeltaSQKQ and EIAV p9 interaction with either full length ALIX, or ALIXDeltaPRR as determined in yeast two-hybrid assay and revealed by alpha-galactosidase expression quantified by densitometry. Data are expressed as percentage of the maximal activity observed after the cotransformation with mutant p6DeltaSQK and ALIX proteins. (C) Interaction determined by GST-pull-down. GST fusion proteins were obtained by subcloning of HIV-1 p6, p6DeltaSQKQ and EIAV p9 domains into pGEX-KT (GE Healthcare). Purified GST-proteins bound to glutathione-beads were mixed with cell lysates containing either ALIX-HA or ALIXDeltaPRR-HA proteins. Co-precipitated proteins were detected by western blotting using an anti-HA monoclonal antibody (Clone HA.11) and quantified by densitometry. Results were expressed in percentage of the band intensity measured in the presence of the GST-p9 construct. Equivalent loads of the GST fusion proteins were verified by Coomassie blue staining of the glutathione-bound fraction. The lanes marked Input contain 10% of the cell extract used for binding experiments. (D) L-domain function as determined using a complementation assay [6, 20, 21, 35]. 293T cells were cotransfected with 300 ng of HIV proviral plasmid (Nldeltap6) that lacks the p6 L domain, 200 ng of plasmid expressing a truncated HIV Gag protein (Gagdeltap6) fused to the p6 domain of Gag mutated on the PTAP L domain (PTAP/LIRL) or to the p6 PTAP/LIRLDeltaSQKQ and 200 ng of plasmid expressing myc tagged ALIX (1-868) or an empty vector. Virion samples pelleted through 20% sucrose cushions, Gag expression and Myc-ALIX were analyzed [21] by western blotting with a mouse antibody anti-HIV CAp24 serum (Biodesign International) and with a monoclonal antibody anti-Myc (Santa Cruz Biotechnology). Virion was also measured 48 h later using an infection assay with MAGIC-5B (HeLa-CD4/CCR5 LTR-lacZ) indicator cells for HIV-1. Error bars in infectivity assays represented standard deviations of three separate experiments.
###end p 21
###begin p 22
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 97 107 97 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
###xml 203 212 199 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ</sub>
###xml 372 374 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 530 539 508 513 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ</sub>
###xml 629 637 603 607 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;PRR</sub>
###xml 645 655 615 621 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
###xml 853 862 815 820 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;PRR </sub>
###xml 946 947 904 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1051 1060 1009 1014 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ</sub>
###xml 792 797 <span type="species:ncbi:4932">yeast</span>
###xml 1007 1012 <span type="species:ncbi:4932">yeast</span>
Therefore a p6 mutant deleted for amino-acids S25 to Q28 (see location in Fig. 2A) referred as p6DeltaSQKQ was produced and was tested for interaction with ALIX by the Y2H assay. p9-ALIX, p6-ALIX, and p6DeltaSQKQ-ALIX gave rise to detectable growth on selective media when incubated for 3 days at 30degreesC, indicating that protein-protein interaction has occurred (Fig. 2B). The binding affinity quantified by in situ alpha-galactosidase staining using X-alpha-Gal as a substrate revealed a quite stronger interaction between p6DeltaSQKQ-ALIX as compared to p6-ALIX and/or p9-ALIX. When tested for binding to the truncated ALIXDeltaPRR, the p6DeltaSQKQ mutant supported significant growth on selective media. alpha-galactosidase staining was however reduced as compared to that observed in yeast co-expressing p9. Under similar conditions, the p6-ALIXDeltaPRR cotransfectants were found unable to grow as expected from data described in Figure 1. The absence of a significant growth on selective media of yeast co-expressing p9-Gal4AD, p6-Gal4AD, p6DeltaSQKQ-Gal4AD and ALIX-Gal4DBD ruled out the possibility that the different bait and prey proteins tested could directly activate the Gal4 responsive promoter and thus validated the specificity of the above described interactions.
###end p 22
###begin p 23
###xml 124 132 124 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;PRR</sub>
###xml 257 266 253 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 279 280 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 309 316 305 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 379 389 375 381 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
###xml 483 491 475 479 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;PRR</sub>
###xml 706 708 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 765 773 753 757 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;PRR</sub>
###xml 832 841 816 821 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ</sub>
###xml 309 316 <span type="species:ncbi:562">E. coli</span>
To confirm these data, GST-pull down assays were then carried out with extracts from cells expressing either ALIX-HA or ALIXDeltaPRR-HA. This truncation was used because the removal of the proline-rich region has been described to improve the efficiency of in vitro interaction [4]. After their expression in E. coli, the following fusion proteins, GST, GST-p6, GST-p9 and GST-p6DeltaSQKQ were bound to glutathione-Sepharose beads, and allowed to interact with either ALIX-HA or ALIXDeltaPRR-HA. After extensive washings, the complexes were eluted, subjected to electrophoresis under denaturing conditions, transferred to a PVDF membrane and reacted with an anti-HA monoclonal antibody. As shown in Figure 2C, the three GST constructs bound to both ALIX-HA and ALIXDeltaPRR-HA proteins in the following strength order: GST-p9>GST-p6DeltaSQKQ>GST-p6 while the control GST displayed no detectable binding activity.
###end p 23
###begin p 24
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 442 443 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 665 675 657 663 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
###xml 772 774 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D</xref>
###xml 920 929 908 913 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ</sub>
###xml 969 979 953 959 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
###xml 91 96 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 319 324 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 449 454 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 575 580 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 685 690 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 873 878 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 902 907 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1179 1184 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1271 1276 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1384 1389 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1482 1487 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The overexpression of wild type ALIX has been shown to partially rescue budding defects of HIV-1 particles with a p6 domain containing mutations in the PTAP motif (called PTAP/LIRL), i.e. unable to recruit the ESCRT I component Tgs101 [17,21]. We therefore tested the ability of ALIX to alleviate the release defect of HIV-1 PTAP/LIRL mutated viruses containing or not the SQKQ deletion. We used a previously described complementation assay [6,21]: HIV-1 proviral plasmid (NLdeltap6) that lacks the p6 domain was cotransfected into 293T with a plasmid expressing a truncated HIV-1 Gag protein (Gagdeltap6) fused to either the PTAP/LIRL p6 domain or the PTAP/LIRL p6DeltaSQKQ domain of HIV-1, together with an expression vector for ALIX or empty vector. As shown in Figure 2D, the coexpression of ALIX led to an increase in viral particle production and infectivity by both HIV-1 PTAP/LIRL p6 virus and HIV-1 PTAP/LIRL p6DeltaSQKQ. Similar effect of ALIX on PTAP/LIRL p6DeltaSQKQ was observed, although with reduced efficiencies. In summary, the deletion amino acid residues located in the p6 hinge region (DeltaSQKQ) enhanced binding to ALIX, and partially allowed the rescue of HIV-1 PTAP/LIRL upon ALIX overexpression. This limited enhancing effect of this deletion on HIV-1 PTAP/LIRL p6 upon ALIX overexpression is indicative of a negative modulation played by the hinge region of HIV-1 p6. This negative modulation would be part of the highly complex process that optimises the HIV-1 budding.
###end p 24
###begin title 25
###xml 23 33 23 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
Mapping of a minimal p6DeltaSQKQ binding site within the middle region of ALIX
###end title 25
###begin p 26
###xml 69 79 69 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
###xml 137 139 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 147 148 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 337 347 333 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
###xml 484 493 476 481 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ</sub>
###xml 578 588 566 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
###xml 694 695 678 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 695 700 679 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">inset</italic>
###xml 733 741 717 725 <sub xmlns:xlink="http://www.w3.org/1999/xlink">391&#8211;510 </sub>
###xml 915 917 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 971 979 955 963 <sub xmlns:xlink="http://www.w3.org/1999/xlink">391&#8211;510 </sub>
###xml 1031 1038 1015 1022 <sub xmlns:xlink="http://www.w3.org/1999/xlink">409&#8211;715</sub>
###xml 1039 1041 1023 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1048 1055 1032 1039 <sub xmlns:xlink="http://www.w3.org/1999/xlink">364&#8211;716</sub>
###xml 1065 1071 1049 1055 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;503 </sub>
###xml 1072 1074 1056 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
To isolate a minimal region in ALIX that was still able to bind to p6DeltaSQKQ we used a previously described Y2H assay called Y2H-TPCR [25] (Fig. 3). Briefly, a library of random ~300 bp long PCR fragments derived from the ALIX cDNA was subcloned downstream to the Gal4 AD, and screened for potential interaction against the Gal4 DBD/p6DeltaSQKQ bait. After selection on selective SD/-Trp/-Leu/-His/-Ade medium, one ALIX fragment encompassing residues 391-510 was found to bind to p6DeltaSQKQ. This fragment also interacted with p9, but not with p6 or with the double mutant p6DeltaSQKQ Y36A unable to bind to ALIX as reported above, thus demonstrating that the interaction was specific (Fig. 3inset). It is worth noticing that ALIX391-510 fragment partially rebuilds the arm 2 of the V-shape domain and encompasses the great majority of the hydrophobic surface residues which presumably contact the late domains [17]. Remarkably, the minimal p6 and p9 binding site ALIX391-510 that we identified are present in the truncated ALIX409-715[15], ALIX364-716, and ALIX1-503 [21] fragments known to bind the YPDL motif.
###end p 26
###begin p 27
###xml 49 58 49 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ</sub>
###xml 0 79 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Y2H-TPCR screening assay used to map the HIV-1 p6<sub>&#916;SQKQ</sub>-binding site in ALIX</bold>
###xml 286 303 282 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 362 372 354 360 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
###xml 702 711 684 689 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ</sub>
###xml 753 758 731 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Inset</italic>
###xml 771 775 745 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SQKQ</italic>
###xml 766 777 744 751 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;<italic>SQKQ</italic>, </sub>
###xml 829 837 803 811 <sub xmlns:xlink="http://www.w3.org/1999/xlink">391&#8211;510 </sub>
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 286 302 <span type="species:ncbi:562">Escherichia coli</span>
###xml 388 393 <span type="species:ncbi:4932">yeast</span>
Y2H-TPCR screening assay used to map the HIV-1 p6DeltaSQKQ-binding site in ALIX. Random tagged PCR was performed using full length AIP-1 DNA sequence as a template according to a previously described technique {Chen, 2005 #33}. The resulting library of AIP-1 fragments was amplified in Escherichia coli DH5alpha. The ALIX library was cotransformed with pGBKT7-p6DeltaSQKQ bait into AH109 yeast and streaked onto SD/-Ade/-His/-Leu/-Trp plates. Clones growing on selective plates after 4-5 days at 30degreesC were recovered by transformation into bacteria, and inserts were sequenced. The amino acid sequence of ALIX (aa: 391-510, REFSEQ: accession NM_013374.3) that is represented, corresponds to the p6DeltaSQKQ-binding fragment identified in this work.Inset: p6, p6DeltaSQKQ, p6 Y36A and p9 were tested for interaction with ALIX391-510 in experimental conditions similar to those described in Figure 2B.
###end p 27
###begin title 28
Conclusion
###end title 28
###begin p 29
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 935 945 935 941 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
###xml 978 986 974 978 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;PRR</sub>
###xml 1296 1298 1288 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1450 1452 1442 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1857 1865 1849 1857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 2471 2473 2463 2465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 2535 2545 2527 2533 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#916;SQKQ </sub>
###xml 3 8 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 323 328 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 808 813 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1064 1069 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2116 2121 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2333 2338 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2633 2638 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2646 2650 <span type="species:ncbi:11665?1.0">EIAV</span>
###xml 2986 2991 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
If HIV-1 budding process is dependent on the presence of both Tsg101 and ALIX proteins, ALIX recruitment by the p6 late domain occurs at relatively low levels. On an evolutionary point of view, it has been proposed [26] that a strong ALIX-binding site in combination with a Tsg101-binding site may confer a disadvantage to HIV-1 perhaps because hyperactivation of ALIX can lead to apoptosis [27]. We identified here what makes p6 a weak ALIX-binding factor. The ALIX-binding site in p6 includes the consensus YPxnL sequence inserted into a leucine triplet repeat motif (Lxx)4. By contrast to p9, p6 is unable to bind to a detectable level to a truncated form of ALIX deleted from its PRR (aa: 716-868). Beside the essential role of the C-terminus of the ALIX PRR in recruiting the ESCRT machinery to promote HIV-1 budding [28], our data support that the PRR could also facilitate the recruitment of p6. The distinct behaviour of the p6DeltaSQKQ mutant, which still binds to ALIXDeltaPRR, sheds some light on a particular structural aspect of p6. Indeed, analyzing HIV-1 subtypes sequenced until now, the p6 domain appears by far the most variable domain in the Gag polyprotein precursor and natural deletions or insertions are frequently observed in the central region of p6 between S14 and I31 [29]. Interestingly, mutation of the 27KQE29 motif has never been observed so far. If K27 residue in this motif is a substrate for ubiquitin modification [30], it is unclear whether Gag itself needs to be ubiquitinylated for budding. The hinge region of p6 adopts a constrained conformation, which prevents optimum binding to ALIX. The deletion of the hinge region that encompasses the highly conserved KQE motif results in an increased affinity of the mutant late domain for ALIX probably by alleviating the bend between N and C terminus of p6. As suggested by in vivo analysis, a tightly interaction between late domain inhibited partially rescue of particle production upon ALIX over-expression. We can speculate that the ALIX-binding site is not necessarily optimized for high-affinity particularly in the context of HIV-1 which employs two late domains. Taken together, these observations point out that the negative activity of the p6 hinge may provide an additional ALIX-dependent regulatory process in the mechanisms that control HIV-1 budding, the complexity of which is far from being fully understood as shown by the recent finding of nucleocapsid binding to ALIX [31]. Finally, by using a random strategy, we have refined the p6DeltaSQKQ and p9 binding site down to the ALIX 391-510 fragment. Furthermore, from our data, both HIV-1 p6 and EIAV p9 bind to an overlapping site on ALIX but in a quite different way. If the interaction between ALIX and p9 is direct, that of p6 to ALIX occurs in two steps. We propose that the PRR domain of ALIX could first contact p6 so as to alleviate the conformational constraints of the p6 hinge region and enable the subsequent binding of the HIV-1 late domain to the ALIX V domain within the 391-510 fragment.
###end p 29
###begin p 30
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 119 124 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 129 133 <span type="species:ncbi:11665?1.0">EIAV</span>
###xml 634 639 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 787 792 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
During the submission of this work the crystal structures of ALIX V domain in complex with short peptides spanning the HIV-1 and EIAV late-domain motifs was reported [32]. Because p6 and p9 peptides, but not the full-length proteins, bind ALIX V domain with similar affinities, the authors proposed that interactions of ALIX with full-length p6 and p9 are regulated by subtle protein context-dependent effects. Our work based on Y2H experiments provides further support to biosensor experiments reported by Zhai et al. [32] and validates a model in which the structural constraints in the hinge region of p6 weaken the binding of the HIV-1 late domain to ALIX. Accordingly, the interaction of p6 late domain with ALIX appears to be a finely tuned process required for optimal budding of HIV-1.
###end p 30
###begin title 31
Abbreviations
###end title 31
###begin p 32
###xml 72 76 <span type="species:ncbi:11665?1.0">EIAV</span>
###xml 78 108 <span type="species:ncbi:11665">equine infectious anemia virus</span>
###xml 110 115 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 117 145 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 319 324 <span type="species:ncbi:4932">yeast</span>
Aa: amino acid; AD: activation domain; Bp: bp; DBD: DNA binding domain; EIAV: equine infectious anemia virus; HIV-1: human immunodeficiency virus type-1; PMSF: phenylmethanesulphonylfluoride; SD: synthetic dropout; SPR: surface plasmon resonance; X-alpha-Gal: 5-Bromo-4-Chloro-3-indolyl alpha-D-galactopyranoside; Y2H: yeast two-hybrid.
###end p 32
###begin title 33
Competing interests
###end title 33
###begin p 34
The authors declare that they have no competing interests.
###end p 34
###begin title 35
Authors' contributions
###end title 35
###begin p 36
DG, NC, LB and J-CC have conceived the study and analyzed data. J-CC, NC and CL performed the laboratory work and wrote the manuscript. CL and NC equally contributed to this work. All the authors have read and approved the manuscript
###end p 36
###begin title 37
Acknowledgements
###end title 37
###begin p 38
###xml 71 75 <span type="species:ncbi:11665?1.0">EIAV</span>
We thank C. Leroux and O. Vincent for providing the molecular clone of EIAV and plasmid pGAD ALIX, respectively, P. Bieniasz for providing plasmid constructs NLdeltap6 and Gagdeltap6 used in complementation experiments. This work was supported by the CNRS, ANRS and the Ministere de la Recherche.
###end p 38
###begin article-title 39
Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I
###end article-title 39
###begin article-title 40
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Beyond Tsg101: the role of Alix in 'ESCRTing' HIV-1
###end article-title 40
###begin article-title 41
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding
###end article-title 41
###begin article-title 42
###xml 35 40 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 48 52 <span type="species:ncbi:11665?1.0">EIAV</span>
AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding
###end article-title 42
###begin article-title 43
###xml 81 84 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag)
###end article-title 43
###begin article-title 44
###xml 23 26 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The protein network of HIV budding
###end article-title 44
###begin article-title 45
###xml 59 64 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function
###end article-title 45
###begin article-title 46
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 10 21 <span type="species:ncbi:205488">Ebola virus</span>
HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress
###end article-title 46
###begin article-title 47
###xml 19 54 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner
###end article-title 47
###begin article-title 48
###xml 82 117 <span type="species:ncbi:11709">human immunodeficiency virus type 2</span>
Tsg101, an inactive homologue of ubiquitin ligase e2, interacts specifically with human immunodeficiency virus type 2 gag polyprotein and results in increased levels of ubiquitinated gag
###end article-title 48
###begin article-title 49
###xml 73 78 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein
###end article-title 49
###begin article-title 50
Structure and functional interactions of the Tsg101 UEV domain
###end article-title 50
###begin article-title 51
###xml 61 66 <span type="species:ncbi:9606">human</span>
###xml 80 85 <span type="species:ncbi:4932">yeast</span>
The ALG-2-interacting protein Alix associates with CHMP4b, a human homologue of yeast Snf7 that is involved in multivesicular body sorting
###end article-title 51
###begin article-title 52
Structural basis for endosomal targeting by the Bro1 domain
###end article-title 52
###begin article-title 53
###xml 69 99 <span type="species:ncbi:11665">equine infectious anemia virus</span>
Functions of early (AP-2) and late (AIP1/ALIX) endocytic proteins in equine infectious anemia virus budding
###end article-title 53
###begin article-title 54
Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding
###end article-title 54
###begin article-title 55
Structural basis for viral late-domain binding to Alix
###end article-title 55
###begin article-title 56
###xml 35 40 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
An Alix fragment potently inhibits HIV-1 budding: characterization of binding to retroviral YPXL late domains
###end article-title 56
###begin article-title 57
###xml 70 75 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Structural and functional studies in vitro on the p6 protein from the HIV-1 gag open reading frame
###end article-title 57
###begin article-title 58
###xml 26 61 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Solution structure of the human immunodeficiency virus type 1 p6 protein
###end article-title 58
###begin article-title 59
Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins
###end article-title 59
###begin article-title 60
MultiCoil: a program for predicting two- and three-stranded coiled coils
###end article-title 60
###begin article-title 61
###xml 77 82 <span type="species:ncbi:9606">human</span>
YPXL/I is a protein interaction motif recognized by aspergillus PalA and its human homologue, AIP1/Alix
###end article-title 61
###begin article-title 62
###xml 25 37 <span type="species:ncbi:11191">Sendai virus</span>
The YLDL sequence within Sendai virus M protein is critical for budding of virus-like particles and interacts with Alix/AIP1 independently of C protein
###end article-title 62
###begin article-title 63
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 85 98 <span type="species:ncbi:11234">measles virus</span>
Inhibition of ubiquitination and stabilization of human ubiquitin E3 ligase PIRH2 by measles virus phosphoprotein
###end article-title 63
###begin article-title 64
###xml 4 9 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
How HIV-1 hijacks ALIX
###end article-title 64
###begin article-title 65
Do Alix and ALG-2 really control endosomes for better or for worse?
###end article-title 65
###begin article-title 66
###xml 17 52 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Potent rescue of human immunodeficiency virus type 1 late domain mutants by ALIX/AIP1 depends on its CHMP4 binding site
###end article-title 66
###begin article-title 67
###xml 77 112 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein
###end article-title 67
###begin article-title 68
###xml 58 93 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 98 127 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 157 186 <span type="species:ncbi:11801">Moloney murine leukemia virus</span>
Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p12Gag protein of Moloney murine leukemia virus
###end article-title 68
###begin article-title 69
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Gag engages the Bro1 domain of ALIX/AIP1 through the nucleocapsid
###end article-title 69
###begin article-title 70
###xml 84 89 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 94 98 <span type="species:ncbi:11665?1.0">EIAV</span>
Structural and functional studies of ALIX interactions with YPX(n)L late domains of HIV-1 and EIAV
###end article-title 70
###begin article-title 71
###xml 77 107 <span type="species:ncbi:11665">equine infectious anemia virus</span>
Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus
###end article-title 71
###begin article-title 72
Site-directed mutagenesis by overlap extension using the polymerase chain reaction
###end article-title 72
###begin article-title 73
Role of ESCRT-I in retroviral budding
###end article-title 73

